カテゴリ： DelveInsight, 医療/バイオ

糖尿病同伴認知症治療薬の世界市場：疫学予測

◆英語タイトル：Dementia with Diabetes - Epidemiology Forecast to 2030
◆商品コード：DELV20JU189
◆発行会社（リサーチ会社）：DelveInsight
◆発行日：2020年7月
◆ページ数：90
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール（受注後2営業日）
◆調査対象地域：アメリカ、ヨーロッパ、日本
◆販売価格オプション（消費税別）
Single User（189名様閲覧）USD3,750 ⇒換算￥405,000見積依頼/購入/質問フォーム
Three UserUSD5,625 ⇒換算￥607,500見積依頼/購入/質問フォーム
Site LicenseUSD7,500 ⇒換算￥810,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
※DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

 【レポートの概要】

DelveInsight’s ‘Dementia with Diabetes—Epidemiology Forecast–2030’ report delivers an in-depth understanding of the disease, historical and forecasted Dementia with Diabetes epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Dementia with Diabetes Understanding
Dementia is a malady—usually of a chronic or progressive nature—in which there is deterioration in cognitive function (i.e., the ability to process thought).

It affects memory, thinking, orientation, comprehension, calculation, learning capacity, language, and judgment. The impairment in cognitive function is commonly accompanied and occasionally preceded, by deterioration in emotional control, social behavior, or motivation. Dementia develops as a result of a complex interplay of clinical and biological factors and is beset by multiple underlying pathological features. People with type 2 diabetes represent a substantial risk group for cognitive impairment and dementia caused by both Alzheimer’s disease dementia and vascular brain injury. Furthermore, type 2 diabetes increases the risk of mortality in patients who already have dementia, suggesting that targeted intervention at any point may improve health outcomes.

Diabetes is a condition in which the amount of glucose in the blood is too high due to defects in insulin secretion, action or both (American Diabetes Association, 2009). Insulin is a hormone produced by the pancreas gland, which controls glucose levels in the blood. If diabetes is not well-controlled or is diagnosed late, people with the condition can develop several disabling complications including blindness, kidney failure, foot ulcers, heart attacks, and stroke. There are two main types of diabetes which majorly includes type 1 and type 2 diabetes.

There are over 100 different types of dementia, but the most common type is Alzheimer’s, vascular dementia, Lewy body dementia, Parkinson’s, CJD, Pick’s disease, and alcohol-related dementia. Although many of the studies examined risk related to all-cause dementia, there is evidence that two specific subtypes, Alzheimer’s disease dementia and vascular dementia, are most strongly associated with type 2 diabetes. Early symptoms include forgetfulness, repetitiveness, short-term memory loss, and difficulty in finding the right words.

Dementia with Diabetes Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Population of Dementia ,Age-specific prevalent population of dementia, Type-specific prevalent population of dementia, Severity-specific Prevalent Population of Alzheimer’s Dementia and Prevalence of Dementia (Alzheimer’s disease) with Diabetes a scenario of Dementia with Diabetes in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Dementia with Diabetes Detailed Epidemiology Segmentation
The total prevalent cases of dementia in 7MM is 21,021,021 in 2017, which is expected to increase in the forecast period
Among the EU5, Germany accounts for the highest prevalent cases of dementia with diabetes followed by UK and France i.e., 173,957, 148,423 and 148,376 cases in 2017 which is estimated to increase in the forecast period.
According to DelveInsight, it is estimated that the type-specific prevalent cases of dementia in Alzheimers disease in the US were 5,796,827 in 2017 which is expected to increase by 2030.
The total prevalent cases of dementia in the UK were found to be 1,450,858 cases in 2017, which is expected to increase in the forecast period.
According to the analysis, in 2017, the higher aged population is commonly affected by dementia. As per the estimates, there were 267,546, 1,426,911, 4,013,188, and 3,210,550 cases of 50-64, 65–74, 75–84, and 85+ in 2017 in the US.
In US (2017), the estimated cases of type specific dementia for Alzheimer’s disease, vascular dementia, Lewy-body dementia, Fronto-temporal dementia, mixed dementia and others are 5,796,827, 1,337,729, 535,092, 89,182, 713,456 and 445,910.
In 2017, the total prevalent case of dementia with diabetes in Japan is expected to increase at a CAGR of 3.56% during the forecast period.
According to the analysis, mild cases accounts for 2,373,801 cases in 2017 followed by 2,484,520 moderate cases and 938,506 severe cases in the US respectively.
Scope of the Report
The report covers the descriptive overview of Dementia with Diabetes, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
The report assesses the disease risk and burden and highlights the unmet needs of Dementia with Diabetes.
The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of Dementia with Diabetes, Total Diagnosed and Treated Cases of Dementia with Diabetes.
Report Highlights
Eleven-Year Forecast of Dementia with Diabetes
7MM Coverage
Prevalent Population of Dementia
Age-specific prevalent population of dementia
Type-specific prevalent population of dementia
Severity-specific Prevalent Population of Alzheimer’s Dementia
Prevalence of Dementia (Alzheimer’s disease) with Diabetes
Key Questions Answered
What is the disease risk, burden and unmet needs of Dementia with Diabetes?
What is the historical Dementia with Diabetes patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
What would be the forecasted patient pool of Dementia with Diabetes at the 7MM level?
What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Dementia with Diabetes?
Out of the countries mentioned above, which country would have the highest prevalent population of Dementia with Diabetes during the forecast period (2020–2030)?
At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?
Reasons to buy
The Dementia with Diabetes report will allow the user to -

Develop business strategies by understanding the trends shaping and driving the 7MM Dementia with Diabetes market.
Quantify patient populations in the 7MM Dementia with Diabetes market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the specific type of Dementia with Diabetes that presents the best opportunities for Dementia with Diabetes therapeutics in each of the markets covered.
The Dementia with Diabetes epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
The Dementia with Diabetes epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.
Key Assessments
Patient Segmentation
Disease Risk and Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population
Geographies Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan
Study Period: 2017–2030

【レポートの目次】

1 Key Insights

2 Executive Summary

3 SWOT Analysis

4 Dementia with Diabetes Market Overview at a Glance

4.1 Patient Share (%) Distribution of Dementia with Diabetes in 2017

4.2 Patient Share (%) Distribution of Dementia with Diabetes in 2030

5 Disease Background and Overview: Dementia with Diabetes

5.1 Introduction

5.2 Dementia

5.2.1 Types of Dementia

5.3 Dementia with Diabetes

5.4 Risk Factor

5.5 Signs and Symptoms of Dementia

5.6 Pathophysiology

5.7 Diagnosis

5.8 Diagnostic Guidelines

6 Recognized Establishments

7 Epidemiology and Patient Population

7.1 Key Findings

7.1 Total Prevalent Population of Dementia in the 7MM

7.2 Prevalence of Dementia (Alzheimer’s disease) with diabetes in the 7MM

7 3MM Epidemiology of Dementia with Diabetes

8. Assumption and Rationale

8.1 United States

8.1.1 Prevalent Population of Dementia in the United States

8.1.2 Age-specific prevalent population of dementia in the United States

8.1.3 Type-specific prevalent population of dementia in the United States

8.1.4 Severity Specific Prevalent Population of Alzheimer’s Dementia in the United States

8.1.5 Prevalence of Dementia (Alzheimer’s disease) with Diabetes in the United States

8.2 EU5 Countries

8.3 Germany

8.3.1 Prevalent Population of Dementia in Germany

8.3.2 Age-specific prevalent population of dementia in Germany

8.3.3 Type-specific prevalent population of dementia in Germany

8.3.4 Severity Specific Prevalent Population of Alzheimer’s Dementia in Germany

8.3.5 Prevalence of Dementia (Alzheimer’s disease) with Diabetes in Germany

8.4 France

8.4.1 Prevalent Population of Dementia in France

8.4.2 Age-specific prevalent population of dementia in France

8.4.3 Type-specific prevalent population of dementia in France

8.4.4 Severity Specific Prevalent Population of Alzheimer’s Dementia in France

8.4.5 Prevalence of Dementia (Alzheimer’s disease) with Diabetes in France

8.5 Italy

8.5.1 Prevalent Population of Dementia in Italy

8.5.2 Age-specific prevalent population of dementia in Italy

8.5.3 Type-specific prevalent population of dementia in Italy

8.5.4 Severity Specific Prevalent Population of Alzheimer’s Dementia in Italy

8.5.5 Prevalence of Dementia (Alzheimer’s disease) with Diabetes in Italy

8.6 Spain

8.6.1 Prevalent Population of Dementia in Spain

8.6.2 Age-specific prevalent population of dementia in Spain

8.6.3 Type-specific prevalent population of dementia in Spain

8.6.4 Severity Specific Prevalent Population of Alzheimer’s Dementia in Spain

8.6.5 Prevalence of Dementia (Alzheimer’s disease) with Diabetes in Spain

8.7 United Kingdom

8.7.1 Prevalent Population of Dementia in the United Kingdom

8.7.2 Age-specific prevalent population of dementia in the United Kingdom

8.7.3 Type-specific prevalent population of dementia in the United Kingdom

8.7.4 Severity Specific Prevalent Population of Alzheimer’s Dementia in the United Kingdom

8.7.5 Prevalence of Dementia (Alzheimer’s disease) with Diabetes in the United Kingdom

8.8 Japan

8.8.1 Prevalent Population of Dementia in Japan

8.8.2 Age-specific prevalent population of dementia in Japan

8.8.3 Type-specific prevalent population of dementia in Japan

8.8.4 Severity Specific Prevalent Population of Alzheimer’s Dementia in Japan

8.8.5 Prevalence of Dementia (Alzheimer’s disease) with Diabetes in Japan

9 Appendix

10 DelveInsight Capabilities

11 Disclaimer

12 About DelveInsight

Table 1: Summary of Dementia with Diabetes Market, Epidemiology and Key Events (2017–2030)

Table 2: Issues for people with dementia/diabetes who develop diabetes/dementia

Table 3: Guideline recommendations for key clinical outcomes for older people with diabetes from Diabetes Canada (DC), American Diabetes Association (ADA) and International Diabetes Federation (IDF)

Table 4: Total Prevalent Population of dementia in the 7MM Countries (2017–2030)

Table 5: Prevalence of Dementia (Alzheimer's disease) with diabetes in the 7MM Countries (2017–2030)

Table 6: Prevalent Population of dementia in the United States (2017–2030)

Table 7: Age-specific prevalent population of dementia in the United States (2017–203

Table 8: Type-specific prevalent population of dementia in the United States (2017–2030)

Table 9: Severity Specific Prevalent Population of Alzheimer's Dementia in the United States (2017–2030)

Table 10: Prevalence of Dementia (Alzheimer's disease) with Diabetes in the United States (2017–2030)

Table 11: Prevalent Population of dementia in Germany (2017–2030)

Table 12: Age-specific prevalent population of dementia in Germany (2017–2030)

Table 13: Type-specific prevalent population of dementia in Germany (2017–2030)

Table 14: Severity Specific Prevalent Population of Alzheimer's Dementia in Germany (2017–2030)

Table 15: Prevalence of Dementia (Alzheimer's disease) with Diabetes in Germany (2017–2030)

Table 16: Prevalent Population of dementia in France (2017–2030)

Table 17: Age-specific prevalent population of dementia in France (2017–2030)

Table 18: Type-specific prevalent population of dementia in France (2017–2030)

Table 19: Severity Specific Prevalent Population of Alzheimer's Dementia in France (2017–2030)

Table 20: Prevalence of Dementia (Alzheimer's disease) with Diabetes in France (2017–2030)

Table 21: Prevalent Population of dementia in Italy (2017–2030)

Table 22: Age-specific prevalent population of dementia in Italy (2017–2030)

Table 23: Type-specific prevalent population of dementia in Italy (2017–2030)

Table 24: Severity Specific Prevalent Population of Alzheimer's Dementia in Italy (2017–2030)

Table 25: Prevalence of Dementia (Alzheimer's disease) with Diabetes in Italy (2017–2030)

Table 26: Prevalent Population of dementia in Spain (2017–2030)

Table 27: Age-specific prevalent population of dementia in Spain (2017–2030)

Table 28: Type-specific prevalent population of dementia in Spain (2017–2030)

Table 29: Severity Specific Prevalent Population of Alzheimer's Dementia in Spain (2017–2030)

Table 30: Prevalence of Dementia (Alzheimer's disease) with Diabetes in Spain (2017–2030)

Table 31: Prevalent Population of dementia in the United Kingdom (2017–2030)

Table 32: Age-specific prevalent population of dementia in the United Kingdom (2017–2030)

Table 33: Type-specific prevalent population of dementia in the United Kingdom (2017–2030)

Table 34: Severity Specific Prevalent Population of Alzheimer's Dementia in the United Kingdom (2017–2030)

Table 35: Prevalence of Dementia (Alzheimer's disease) with Diabetes in the United Kingdom (2017–2030)

Table 36: Prevalent Population of dementia in Japan (2017–2030)

Table 37: Age-specific prevalent population of dementia in Japan (2017–2030)

Table 38: Type-specific prevalent population of dementia in Japan (2017–2030)

Table 39: Severity Specific Prevalent Population of Alzheimer's Dementia in Japan (2017–2030)

Table 40: Prevalence of Dementia (Alzheimer's disease) with Diabetes in Japan (2017–2030)

List of Figures

Figure 1: Dementia with Diabetes SWOT Analysis

Figure 2: Types of Dementia

Figure 3: Major Types of Dementia

Figure 4: Risk factor of Dementia

Figure 5: Signs and Symptoms of Dementia

Figure 6: Pathophysiologic factors associated with dementia and diabetes in the elderly

Figure 7: The potential role of insulin in the pathogenesis of dementia

Figure 8: Proposed pathophysiological mechanisms linking diabetes to changes in the brain and dementia

Figure 9: Total Prevalent Population of dementia in the 7MM Countries (2017–2030)

Figure 10: Prevalence of Dementia (Alzheimer's disease) with diabetes in the 7MM Countries (2017–2030)

Figure 11: Prevalent Population of dementia in the United States (2017–2030)

Figure 12: Age-specific prevalent population of Dementia in the United States (2017–2030)

Figure 13: Type-specific prevalent population of dementia in the United States (2017–2030)

Figure 14: Severity Specific Prevalent Population of Alzheimer's Dementia in the United States (2017–2030)

Figure 15: Prevalence of Dementia (Alzheimer's disease) with Diabetes in the United States (2017–2030)

Figure 16: Prevalent Population of dementia in Germany (2017–2030)

Figure 17: Age-specific prevalent population of Dementia in Germany (2017–2030)

Figure 18: Type-specific prevalent population of dementia in Germany (2017–2030)

Figure 19: Severity Specific Prevalent Population of Alzheimer's Dementia in Germany (2017–2030)

Figure 20: Prevalence of Dementia (Alzheimer's disease) with Diabetes in Germany (2017–2030)

Figure 21: Prevalent Population of dementia in France (2017–2030)

Figure 22: Age-specific prevalent population of Dementia in France (2017–2030)

Figure 23: Type-specific prevalent population of dementia in France (2017–2030)

Figure 24: Severity Specific Prevalent Population of Alzheimer's Dementia in France (2017–2030)

Figure 25: Prevalence of Dementia (Alzheimer's disease) with Diabetes in France (2017–2030)

Figure 26: Prevalent Population of dementia in Italy (2017–2030)

Figure 27: Age-specific prevalent population of Dementia in Italy (2017–2030)

Figure 28: Type-specific prevalent population of dementia in Italy (2017–2030)

Figure 29: Severity Specific Prevalent Population of Alzheimer's Dementia in Italy (2017–2030)

Figure 30: Prevalence of Dementia (Alzheimer's disease) with Diabetes in Italy (2017–2030)

Figure 31: Prevalent Population of dementia in Spain (2017–2030)

Figure 32: Age-specific prevalent population of Dementia in Spain (2017–2030)

Figure 33: Type-specific prevalent population of dementia in Spain (2017–2030)

Figure 34: Severity Specific Prevalent Population of Alzheimer's Dementia in Italy (2017–2030)

Figure 35: Prevalence of Dementia (Alzheimer's disease) with Diabetes in Spain (2017–2030)

Figure 36: Prevalent Population of dementia in the United Kingdom (2017–2030)

Figure 37: Age-specific prevalent population of Dementia in the United Kingdom (2017–2030)

Figure 38: Type-specific prevalent population of dementia in the United Kingdom (2017–2030)

Figure 39: Severity Specific Prevalent Population of Alzheimer's Dementia in the United Kingdom (2017–2030)

Figure 40: Prevalence of Dementia (Alzheimer's disease) with Diabetes in the United Kingdom (2017–2030)

Figure 41: Prevalent Population of dementia in Japan (2017–2030)

Figure 42: Age-specific prevalent population of Dementia in Japan (2017–2030)

Figure 43: Type-specific prevalent population of dementia in Japan (2017–2030)

Figure 44: Severity Specific Prevalent Population of Alzheimer's Dementia in Japan (2017–2030)

Figure 45: Prevalence of Dementia (Alzheimer's disease) with Diabetes in Japan (2017–2030)

【免責事項】
https://www.marketreport.jp/reports-disclaimer
★医療情報レポート[糖尿病同伴認知症治療薬の世界市場：疫学予測]についてメールでお問い合わせはこちら

※関連の医療情報レポート

  1. 先端巨大症・巨人症の世界市場：疫学予測
    DLVE704028 / DelveInsight / 2017年4月 / ...DelveInsight’s“Acromegaly and Gigantism- Epidemiology Forecast to 2023” Report provides an overview of the epidemiology trends of Acromegaly in seven major markets (US, France, Germany, Italy, Spain, UK and Japan) and Gigantism in six major markets (US, United Kingdom, France, Germany, Italy and Spain). It includes 10 years epidemiology historical and forecasted data of prevalent cases of Acromegaly and Gigantism by age, sex and sub populations. The Report also discusses the prevailing risk factors, disease burden with special emphasis. Acromegaly is a rare but serious hormonal disorder caused by excessive growth hormone (GH) in the blood in adults. Acromegaly in adults...
  2. 多発性硬化症(MS)疫学予測
    DELV803011 / DelveInsight / 2018年3月 / ...DelveInsight’s ‘Multiple Sclerosis - Epidemiology Forecast to 2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Multiple Sclerosis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan. Geography Covered • The United States • EU5 (Germany, France, Italy, Spain and the United Kingdom) • Japan Study Period: 2016-2027 Multiple Sclerosis Epidemiology The Multiple Sclerosis (MS) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Multiple Sclerosis are studied through all possible division to give a better...
  3. 糖尿病網膜症治療の世界市場：疫学予測
    DLVE704023 / DelveInsight / 2017年3月 / ...DelveInsight’s Diabetic Retinopathy - Epidemiology Forecast to 2023 Report provides an overview of the epidemiology trends of Diabetic Retinopathy in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Diabetic Retinopathy prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with the Diabetic Retinopathy. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by DelveInsight team...
  4. ウェスト症候群治療薬の世界市場：疫学予測
    DELV20JU229 / DelveInsight / 2020年6月 / ...DelveInsight’s ‘West Syndrome - Epidemiology Forecast–2030’ report delivers an in-depth understanding of the disease, historical and forecasted West Syndrome epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Geographies Covered The United States EU5 (Germany, France, Italy, Spain, and the United Kingdom) Japan Study Period: 2017–2030 West Syndrome Understanding West syndrome is an age-related specific epileptic encephalopathy due to multiple and diverse causes. It is characterized by a unique type of seizure called epileptic (infantile) spasms and gross EEG abnormalities of hypsarrhythmia. Usually, West syndrome consists of a characteristic triad: infantile spasms, the arrest...
  5. 温かい自己免疫性溶血性貧血（WAIHA）治療薬の世界市場：疫学予測
    DELV20JU228 / DelveInsight / 2020年5月 / ...DelveInsight’s ‘Warm Autoimmune Hemolytic Anemia (WAIHA)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Warm Autoimmune Hemolytic Anemia in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan. Geography Covered • The United States • EU5 (Germany, France, Italy, Spain and the United Kingdom) • Japan Study Period: 2017–2030 Warm Autoimmune Hemolytic Anemia Disease Understanding Autoimmune hemolytic anemia (AIHA) is defined as the increased destruction of red blood cells (RBCs) in the presence of anti-RBC autoantibodies with or without complement activation. W-AIHA is the most common type...
  6. レノックスガストー症候群治療薬の世界市場：疫学予測
    DELV20JU210 / DelveInsight / 2020年7月 / ...DelveInsight’s ‘Lennox Gastaut Syndrome (LGS) - Epidemiology Forecast - 2030’ report delivers an in-depth understanding of the Lennox Gastaut Syndrome (LGS), historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Lennox Gastaut Syndrome (LGS) Disease Understanding Lennox–Gastaut syndrome (LGS) is a severe pediatric epilepsy syndrome characterized by the presence of multiple pharmaco-resistant seizure types, including tonic, atypical absences, and tonic or atonic drop attacks, and the presence of electroencephalographic abnormalities, such as slow-spike waves and paroxysmal fast rhythms. Intellectual disability, behavioral and psychiatric disorders are common comorbidities; and these disturbances...
  7. 坐骨神経痛治療薬の世界市場：疫学予測
    DELV20JU223 / DelveInsight / 2020年6月 / ...DelveInsight's 'Sciatica - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Sciatica epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Geographies Covered The United States EU5 (Germany, France, Italy, Spain, and the United Kingdom) Japan Study Period: 2017-2030 Sciatica Understanding Sciatica is a pain in the lower extremity resulting from irritation of the sciatic nerve. The pain of Sciatica is typically felt from the low-back (lumbar area) to behind the thigh and can radiate down below the knee. The sciatic nerve is...
  8. 慢性腎臓病治療薬の世界市場：疫学予測
    DELV20JU184 / DelveInsight / 2020年5月 / ...DelveInsight’s ‘Chronic kidney disease (CKD)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Chronic kidney disease in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan. Geographies Covered The United States EU5 (Germany, France, Italy, Spain, and the United Kingdom) Japan Study Period: 2017-2030 Chronic Kidney Disease Understanding Chronic kidney disease (CKD) is a type of kidney disease in which there is gradual loss of kidney function over a period of months to years. The initial symptoms include leg swelling, feeling tired, vomiting, loss of appetite, and...
  9. 前頭側頭型認知症治療薬の世界市場：疫学予測
    DELV20JU168 / DelveInsight / 2020年5月 / ...DelveInsight's ' Frontotemporal Dementia - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Frontotemporal Dementia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Geographies Covered The United States EU5 (Germany, France, Italy, Spain, and the United Kingdom) Japan Study Period: 2017-2030 Frontotemporal Dementia Understanding The DelveInsight Frontotemporal Dementia epidemiology report gives a thorough understanding of the Frontotemporal Dementia by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Frontotemporal Dementia in...
  10. ループス腎炎治療の世界市場：疫学予測
    DLVE704019 / DelveInsight / 2017年3月 / ...DelveInsight’s “Lupus Nephritis - Epidemiology Forecast To 2023” Report provides an overview of the disease and global historical and forecasted epidemiological data for the prevalent, diagnosed and treatable cases of Lupus Nephritis from 2013-2023 for the 7MM (United States, EU5 (France, Germany, Italy, Spain and UK) and JapanLupus Nephritis is the most common kidney disorder caused by the life-threatening autoimmune disease such as Systemic Lupus Erythematosus (SLE). It is a leading cause of morbidity and mortality in patients with Systemic Lupus Erythematosus. It leads to inflammation of small blood vessels which play an important role in filtering waste materials in...

◆H&Iグローバルリサーチ株式会社のお客様（例）◆